
The MI Cancer Seek® platform provides comprehensive tissue-based molecular profiling through simultaneous DNA and RNA sequencing, while Caris Assure® offers blood-based analysis of circulating tumor-derived nucleic acids. Because tissue and liquid biopsy can provide complementary information, using both may help clinicians gain a broader molecular picture of a patient's cancer at diagnosis and during treatment. Learn more: ow.ly/FxO550ZYei1
















